SCHEMBL1753524

SCHEMBL1753524

O=C(Nc1ccon1)c1cccc(-n2cnc3c(=O)n(-c4ccc(Cl)cc4)c(-c4ccc(-c5ccccc5)cc4)nc32)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPK14 Q16539 4/20 0.40
YTHDC1 Q96MU7 1/20 0.40
ADORA3 P0DMS8 1/20 0.39
MCHR1 Q99705 1/20 0.39
MAPT P10636 1/20 0.39
SUCNR1 Q9BXA5 1/20 0.38
DYRK3 O43781 1/20 0.38
LCK P06239 1/20 0.38
CSF1R P07333 1/20 0.38
LYN P07948 1/20 0.38
KIT P10721 1/20 0.38
FRK P42685 1/20 0.38
PRKCD Q05655 1/20 0.38
SRPK1 Q96SB4 1/20 0.38
MAP3K20 Q9NYL2 1/20 0.38
KDR P35968 1/20 0.38
GRM5 P41594 1/20 0.38
PYGM P11217 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1753391 0.86 YTHDC1 (0.51) TSHRYTHDC1MCHR1MAPTKDM4E
SCHEMBL1753126 0.85 MAPT (0.44) YTHDC1MCHR1MAPT
SCHEMBL1753442 0.85 SIRT2 (0.45) MAPTCSF1RKDRKMT2AKDM4E
SCHEMBL1689058 0.84 CNR1 (0.44) SMN1; SMN2YTHDC1MCHR1MAPTKMT2A
SCHEMBL12091892 0.83 MAPT (0.59) TSHRSMN1; SMN2MAPK14MAPTDYRK3
SCHEMBL1753322 0.82 CNR1 (0.50) SMN1; SMN2YTHDC1MAPTHPGD
SCHEMBL1688994 0.82 KMT2A (0.44) SMN1; SMN2YTHDC1MCHR1MAPTKMT2A
SCHEMBL1689331 0.81 TP53 (0.47) YTHDC1MCHR1MAPTKMT2AMEN1
SCHEMBL1753237 0.81 GABRA2 (0.47) YTHDC1MCHR1MAPTCSF1RKMT2A
SCHEMBL1689332 0.80 GRM1 (0.48) TSHRSMN1; SMN2MCHR1MAPTGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 US claimed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 US claimed
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 US disclosed
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 US disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 US disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 US disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 US disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 US disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 US disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH TSHR 2250/4885SMN1; SMN2 3746/4885MAPK14 2398/4885
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH TSHR 2250/4885SMN1; SMN2 3746/4885MAPK14 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.